Clinical-stage biopharmaceutical firm Poolbeg will de-list from AIM if merger goes ahead
Shares Magazine
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of directors' buys and sells
- Articles from Shares magazine
